← Product Code [JWH](/submissions/OR/subpart-d%E2%80%94prosthetic-devices/JWH) · K103837 # BALANCED KNEE SYSTEM REVISION OFFSET TIBIA (K103837) _Ortho Development · JWH · Mar 24, 2011 · Orthopedic · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/OR/subpart-d%E2%80%94prosthetic-devices/JWH/K103837 ## Device Facts - **Applicant:** Ortho Development - **Product Code:** [JWH](/submissions/OR/subpart-d%E2%80%94prosthetic-devices/JWH.md) - **Decision Date:** Mar 24, 2011 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 888.3560 - **Device Class:** Class 2 - **Review Panel:** Orthopedic - **Attributes:** Therapeutic ## Intended Use The Balanced Knee System Revision Offset Tibia is intended for use with the Balanced Knee System in total knee arthroplasty procedures, previously failed surgical attempts where bone loss may require the use of augments or stem extensions, or difficult primary surgical cases where a long extension stem is necessary. ## Device Story Modular orthopedic implant system for primary and revision knee arthroplasty; components include offset tibial tray, adapter, screw, and stem. Machined from titanium alloy (Ti-6Al-4V ELI). Used by orthopedic surgeons in clinical settings to address bone loss or complex primary cases requiring long extension stems. Provides structural support for knee joint reconstruction. Mechanical performance validated via fatigue and static load testing. ## Clinical Evidence Bench testing only. No clinical data provided. Mechanical validation included tibial tray fatigue testing and progressive static load testing to ensure the device withstands anticipated in vivo loading and cycling. ## Technological Characteristics Modular tibial tray system; material: titanium alloy (Ti-6Al-4V ELI); semi-constrained cemented prosthesis; design includes offset tray, adapter, screw, and stem components. ## Regulatory Identification A knee joint patellofemorotibial polymer/metal/polymer semi-constrained cemented prosthesis is a device intended to be implanted to replace a knee joint. The device limits translation and rotation in one or more planes via the geometry of its articulating surfaces. It has no linkage across-the-joint. This generic type of device includes prostheses that have a femoral component made of alloys, such as cobalt-chromium-molybdenum, and a tibial component or components and a retropatellar resurfacing component made of ultra-high molecular weight polyethylene. This generic type of device is limited to those prostheses intended for use with bone cement (§ 888.3027). ## Predicate Devices - Balanced Knee Modular Tibial System ([K031201](/device/K031201.md)) - Offset Tibial Tray ([K010212](/device/K010212.md)) - Revision Knee System ([K043440](/device/K043440.md)) ## Reference Devices - Balanced Knee System ([K994370](/device/K994370.md)) - Balanced Knee System Revision ([K060569](/device/K060569.md)) - Balanced Knee Tibial Tray Pegged ([K020383](/device/K020383.md)) - BKS Ultra Congruent ([K090705](/device/K090705.md)) ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0}------------------------------------------------ # 3837 MAR 2 4 2011 ## 510(k) Summary | NAME OF SPONSOR: | Ortho Development Corporation
12187 South Business Park Drive
Draper, Utah 84020 | |----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | 510(k) CONTACT: | Tom Haueter
Regulatory Affairs Manager
Telephone: (801) 553-9991
Facsimile: (801) 553-9993
Email: thaueter@orthodevelopment.com | | DATE PREPARED: | December 22, 2010 | | PROPRIETARY NAME: | Balanced Knee System Revision Offset Tibia | | COMMON NAME: | Offset Tibial Tray Prosthesis | | CLASSIFICATION: | 21 CFR 888.3560, Knee joint, patellofemorotibial,
polymer/metal/polymer semi-constrained cemented prosthesis,
Class II device | | DEVICE PRODUCT CODE: | JWH | | PREDICATE DEVICES: | Balanced Knee Modular Tibial System (K031201)
Ortho Development Corp.
Offset Tibial Tray (K010212)
Biomet
Revision Knee System (K043440)
Smith & Nephew | #### Device Description The proposed Balanced Knee System Revision Offset Tibia is a modular system intended for primary and revision knee surgery. It consists of an offset tibial tray, adapter, screw, and stem. All components are machined from titanium alloy (Ti-6Al-4V ELI). Mechanical testing shows that the Balanced Knee System Revision Offset Tibia can withstand anticipated in vivo loading and cycling. The Balanced Knee System revision Offset Tibia is an addition to the Balanced Knee System. The Balanced Knee System is comprised of: Offset Tibia 510(k) Section 5, 510(k) Summary {1}------------------------------------------------ Balanced Knee System (K994370) Balanced Knee System Revision (K060569) Balanced Knee Modular Tibial System (K031201) Balanced Knee Tibial Tray Pegged (K020383) BKS Ultra Congruent (K090705) ### Intended Use The Balanced Knee System Revision Offset Tibia is intended for use with the Balanced Knee System in total knee arthroplasty procedures, previously failed surgical attempts where bone loss may require the use of augments or stem extensions, or difficult primary surgical cases where a long extension stem is necessary. ### Indications for Use The Balanced Knee System is indicated for use in total knee arthroplasty procedures, for cemented use only. Total knee arthroplasty is indicated for the following conditions: - 1. Loss of joint configuration and joint function. - 2. Osteoarthritis of the knee joint. - 3. Rheumatoid arthritis of the knee joint. - 4. Post-traumatic arthritis of the knee joint. - 5. Valgus, varus, or flexion deformities. - Revision procedures where other treatments or devices have failed. 6. #### Basis for Substantial Equivalence Ortho Development believes that the Balanced Knee System Revision Offset Tibia is substantially equivalent to the previously cleared predicate devices based on similarities in intended use, design, materials, manufacturing methods, packaging, and mechanical performance. The Tests for substantial equivalence include Tibial Tray fatigue and progressive static load mechanical tests, as well as assembly and disassembly tests. ### Section 5, 510(k) Summary {2}------------------------------------------------ Image /page/2/Picture/1 description: The image shows the logo for the Department of Health & Human Services USA. The logo features a stylized eagle with three stripes extending from its back, representing the department's commitment to health, human services, and the well-being of the nation. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" is arranged in a circular pattern around the eagle. Food and Drug Administration 10903 New Hampshire Avenue Document Control Room -WO66-G609 Silver Spring, MD 20993-0002 Ortho Development Corporation % Mr. Tom Haueter Regulatory Affairs Manager 12187 South Business Park Drive Draper, Utah 84020 MAR 2 4 20H Re: K103837 Trade/Device Name: Balanced K.nee System Revision Offset Tibia Regulation Number: 21 CFR 888.3560 Regulation Name: Knee joint patellofemorotibial polymer/metal/polymer semi-contrained cemented prosthesis Regulatory Class: Class II Product Code: JWH Dated: December 22, 2010 Received: December 30, 2010 Dear Mr. Haueter: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. {3}------------------------------------------------ Page 2 - Mr. Tom Haueter Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance, You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Sincerely yours, Ating B. Rutan Mark N. Melkerson Director Division of Surgical, Orthopedic And Restorative Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {4}------------------------------------------------ # Indication for Use Form Ortho Development Balanced Knee System Revision Offset Tibia 510(k) 510(k) Number (if known): K103837 Device Name: Balanced Knee System Revision Offset Tibia Indications for Use: The Balanced Knee System Revision Offset Tibia is indicated for use in total knee arthroplasty procedures, for cemented use only. Total knee arthroplasty is indicated for the following conditions: 1. Loss of joint configuration and joint function. 2. Osteoarthritis of the knee joint. 3. Rheumatoid arthritis of the knee joint. 4. Post-traumatic arthritis of the knee joint. 5. Valgus, varus, or flexion deformities. 6. Revision procedures where other treatments or devices have failed. Prescription Use _____________________________________________________________________________________________________________________________________________________________ X (Part 21 CFR 801 Subpart D) AND/OR Over-The-Counter Use (21 CFR 801 Subpart C) (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of In Device Evaluation (ODE) Page 1 of 1 for M. Melkerson (Division Sign-Off) Division of Surgical, Orthopedic, and Kestorative Devices 510(k) Number K103837 --- **Source:** [https://fda.innolitics.com/submissions/OR/subpart-d%E2%80%94prosthetic-devices/JWH/K103837](https://fda.innolitics.com/submissions/OR/subpart-d%E2%80%94prosthetic-devices/JWH/K103837) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com